CO.DON

Focus: CO.DON is a German biotechnology company specializing in cell therapies, with a focused pipeline in cartilage regeneration. The company operates as a mid-cap biotech with a single lead program in advanced clinical development.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About CO.DON

AI assessmentNot Hiring

No open roles listed right now. Follow CO.DON to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

co.don chondrosphere®

Large Articular Cartilage Lesions of the Femoral

Phase 2

Clinical Trials (1)

NCT01225575Assessment of Efficacy and Safety of 3 Different Doses of co.Don Chondrosphere to Treat Large Cartilage Defects

Phase 2

Help build intelligence for CO.DON

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused pipeline with two active trials in cartilage repair, a high-value orthopedic market with limited competition
Opportunity to contribute to a specialized cell therapy platform (chondrosphere®) advancing toward Phase 3 completion
European biotech base in Germany provides exposure to EU regulatory pathway and regenerative medicine expertise

Watch Out For

No active hiring posted (0 open positions) suggests limited near-term growth or restructuring phase
Pre-revenue stage with opaque financials and funding status creates uncertainty around cash runway and sustainability
Single-program dependency makes career stability contingent on chondrosphere® clinical success

Generated by Claude from CO.DON's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

co.don chondrosphere®

Articular Cartilage Lesion of the Femoral Condyle

Phase 3

Clinical Trials (1)

NCT01222559Efficacy and Safety Study of co.Don Chondrosphere to Treat Cartilage Defects

Phase 3

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo